Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

Executive Summary

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.


Related Content

Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
Hikma To Divest Phenytoin, Promethazine Injectables To Acquire Baxter Business
Impax Gains Products In Watson Deal With FTC To Finalize Arrow Acquisition
Sun Clears FTC Hurdle For Taro Acquisition; Sells Carbamezapine To Fellow Indian Co. Torrent
Mylan/Merck KGaA To Divest Five Generic Drugs To Clear Antitrust Hurdle For Acquisition
FTC Clearance Of Watson’s Andrx Acquisition Requires 13 Generic Divestitures
FTC Clears Barr’s Acquisition Of Pliva Based On Divestiture Of Generic Drugs
Teva/Ivax Merger Gets FTC OK Pending Divestitures
Novartis' Purchase Of Eon Clears FTC; Amide Gets Three Divested Generics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts